Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 7 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

7Total

Not Applicable (2)

P 2 (2)

P 3 (2)

P 4 (1)

Trial Status

Completed7

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT06184399Phase 2Completed

Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC

NCT06188715Phase 3Completed

Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC

NCT04700423Phase 2Completed

Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

NCT04726969Phase 3Completed

Efficacy and Safety of MOX/ALB Co-administration

NCT01658774Not ApplicableCompleted

Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children

NCT00659997Phase 4CompletedPrimary

Efficacy Albendazole and Levamisole Against STH on Unguja

NCT00207753Not ApplicableCompletedPrimary

Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections

Showing all 7 trials

Ascariasis